…
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.…
Eli Lilly has made inroads in the red-hot weight-loss market thanks to its diabetes blockbuster, Mounjaro.…
…
…
Amgens update fueled concerns about potential new competition in the weight loss drug market, sending shares of Novo Nordisk and…
Novo Nordisk, Eli Lilly drop on Amgen competition concerns…
…
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.…
Heres what could happen next to Eli Lilly shares.…
Amgen is among several drugmakers racing to join the red-hot weight loss drug space dominated by Novo Nordisk and Eli…
Novo Nordisk A/S is shipping more introductory doses of its blockbuster weight-loss drug Wegovy in the US as it grapples…
…
…
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound…
LLY earnings call for the period ending March 31, 2024.…
The worlds most valuable drugmaker hiked its full-year sales and profit guidance, despite missing lighter-than-expected first-quarter revenue.…
These were some of the stocks making the largest moves in trading on Tuesday.…
These are some of the stocks posting the largest moves in premarket trading.…
Eli Lilly and Co (NYSE:LLY)’s weight loss medication Mounjaro drove impressive first-quarter earnings results for the US pharmaceuticals megacap. Mounjaro...…
INDIANAPOLIS (dpa-AFX) - Der US-Pharmakonzern Eli Lilly ist dank gut laufender Geschäfte mit Abnehmmitteln mit…
Eli Lilly, 3M, PayPal rise premarket; Coca-Cola, Tesla, McDonalds fall…
Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in…
Eli Lilly stock climbs on gross margin beat, raised 2024 revenue outlook…
Eli Lilly lifts profit view on diabetes and weight-loss drug strength…
Eli Lilly on Tuesday raised its full-year profit forecast, betting on surging demand for its weight-loss treatment Zepbound and type…
…
Booming demand for weight loss and diabetes drugs like Ozempic, Wegovy, Mounjaro and Zepbound has vastly outpaced Novo Nordisk and…
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024…
The Food and Drug Administration said supplies of Zepbound and Mounjaro are expected to be limited through the second quarter,…
Theres no stopping this high-flying biotech.…
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.…
GREIFSWALD (dpa-AFX) - Die Greifswalder Pharmafirma Cheplapharm ist weiter auf Wachstumskurs. Im Geschäftsjahr 2023 sei ein…
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and…
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk…
…
…
Altimmune has a modest market cap but an incredibly promising GLP-1 drug.…
The insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk…
These are the stocks posting the largest moves in the premarket.…
The Eli Lilly and Co (NYSE:LLY) weightloss drug Tirzepatide, known as Zepbound and Mounjaro, has also been shown in two trials to help…
…
The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S.…
Todays Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN)…
Atossa Therapeutics Inc (NASDAQ:ATOS) and its research partner Quantum Leap Healthcare Collaborative announced the initiation of a new study evaluating...…
A staggering $1 trillion could be the annual cost to the US healthcare system if 40% of Americans with obesity begin…
…
A conversation TheStreet engaged in with Cuban about weight-loss drugs shifted from Novo Nordisks Ozempic to something new from Eli…
Analysts see weak trends for Trulicity, which led all Eli Lilly drugs in sales last year. But that wont keep…
The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lillys…